Genentech Places Bet On Polymer Nanoparticle-Based Delivery With GenEdit Deal

Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.